Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to inactivate the target gene, kallikrein B1 (KLKB1), to potentially prevent life-threatening swelling attacks in people with HAE.

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

CRISPR Therapeutics

Exelixis

2023 could be a landmark year for CRISPR Therapeutics. Exelixis has solid fundamentals, plus plenty of upside potential.

3 Beaten-Down Stocks That Could Soar This Year

Beam Therapeutics

Editas Medicine

Novartis

Regeneron Pharmaceuticals

Verve Therapeutics

Vertex Pharmaceuticals

These CRISPR stocks could be big winners for patient investors.

Investing in Top CRISPR Companies

Tesla

Tesla's business has flourished in recent years with profits and revenue both skyrocketing. Intellia Therapeutics has seen rising and falling investor sentiment as it seeks product approval.

2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash

With multiple promising candidates in its pipeline, Intellia is well-positioned to capitalize on the growing demand for gene editing therapies. The recent clearance of its IND application by the FDA for NTLA-2002 for hereditary angioedema is a significant milestone that could significantly change the disease's treatment.

Intellia Therapeutics: Progressing Pipeline Signals Positive Outlook For Investors

Adyen NV

Caterpillar

Magna International

NVIDIA

Investing in Cathie Wood stocks means directing your money toward innovation. And that means investing heavily in tech, a sector that has been pummeled by interest rates held higher by a Federal Reserve battling runaway inflation.

7 Cathie Wood Stocks for Your March Buy List

Amid yet another soft session on Wall Street, biotechnology firm Intellia Therapeutics (NASDAQ: NTLA ) brightened the room considerably. Receiving a regulatory green light from the Food and Drug Administration (FDA), Intellia can now begin testing its CRISPR gene-editing technology in human patients.

Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today?

Intellia Therapeutics landed a historic regulatory nod from the FDA.

Why Intellia Therapeutics Stock Jumped This Week

The FDA cleared Intellia to begin testing its CRISPR gene-editing technology in people on Thursday, leading NTLA stock to jump. The post Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing appeared first on Investor's Business Daily.

Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing

Shares of Intellia Therapeutics Inc. NTLA, +1.44% rallied about 10% in premarket trading on Thursday after the company said the Food and Drug Administration will allow its experimental CRISPR therapy to move into the Phase 2 part of the Phase 1/2 clinical trial. The single-dose therapy is being assessed as a treatment for hereditary angioedema, a rare disorder that causes severe swelling.

Intellia's stock jumps as CRISPR therapy moves into Phase 2 clinical trial

NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.

Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Maury Raycroft - Jeffries Greg Harrison - Bank of America Swapnil Malekar - Piper Sandler Terence Flynn - Morgan Stanley Yanan Zhu - Wells Fargo Rick Bienkowski - Cantor Fitzgerald Raju Prasad - William Blair Dae Gon Ha - Stifel Debjit Chattopadhyay - Guggenheim Rich Law - Credit Suisse Jay Olson - Oppenheimer Brian Cheng - JP Morgan Joseph Thome - Cowen & Company Operator Good morning and welcome to the Intellia Therapeutics' Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Drew and I will be your conference operator today.

Intellia Therapeutics, Inc. (NTLA) Q4 2022 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2022.

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year.

Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?

Denali Therapeutics

Zai Lab Ltd.

Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the lives of millions of patients with a wide range of diseases.

3 More Mid-Cap Biotechs The Street Sees Doubling

The two clinical-stage gene-editing companies have good long-term prospects.

Better Buy: Beam Therapeutics or Intellia Therapeutics?

Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Should You Buy?

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET.

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

PDS Biotechnology Corporation

These cutting-edge biotech stocks hold tremendous upside potential.

3 Deeply Undervalued Stocks That Could Double Your Money

COMPASS Pathways

Ginkgo Bioworks Holdings

These stocks are risky. But they just might deliver huge gains if analysts are right.

3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street

The mean of analysts' price targets for Intellia Therapeutics, Inc. (NTLA) points to a 145.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to Trade

ARK Innovation ETF

Cathie Wood is bullish about these stocks. And so are Wall Street analysts.

3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%

Allogene Therapeutics Inc

Seagen

Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.

News for Intellia Therapeutics Stock (NTLA)